Advanced Enzyme FY26 Results: ₹7,458 mn, ₹1.35 Dividend

Key takeaway from FY26 earnings

Advanced Enzyme Technologies Limited reported higher revenue and profit for FY26, supported by a stronger fourth quarter. The company said its Board of Directors approved audited standalone and consolidated results for the year ended March 31, 2026, along with Q4 results, at a meeting held on May 09, 2026. Consolidated revenue from operations rose to ₹7,457.57 million, while consolidated net profit increased to ₹1,736.08 million. On a standalone basis, revenue from operations came in at ₹4,527.66 million with net profit of ₹1,318.06 million. Alongside the results, the board recommended a final dividend of ₹1.35 per equity share, subject to shareholder approval at the upcoming AGM. The company also announced an investor and analyst conference call scheduled for May 12, 2026.

Board meeting decisions and regulatory disclosure

The company disclosed that the board meeting on May 09, 2026 approved the audited annual financial results for FY26 and audited results for Q4 FY26. The final dividend recommendation was set at ₹1.35 per equity share, which the company described as 67.5% on the face value of ₹2 per share. The recommendation is subject to shareholder approval at the ensuing 37th Annual General Meeting. The board also approved director reappointments and related appointments, to be placed before shareholders at the AGM. In addition, the company disclosed an ESOP-related share allotment under its Employees Stock Options Scheme 2022. Separately, Advanced Enzyme said it had scheduled a conference call for analysts and investors, disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidated FY26 performance: revenue and profit up

Advanced Enzyme reported a year-on-year rise in consolidated revenue from operations to ₹7,457.57 million from ₹6,369.10 million in FY25. Consolidated net profit for FY26 increased to ₹1,736.08 million compared with ₹1,339.74 million in the previous year. The company also reported total comprehensive income of ₹2,684.19 million for FY26 versus ₹1,527.96 million in FY25. In the material shared, the company’s FY26 profit margin was stated at 23.26% based on reported consolidated revenue and profit after tax figures. The company also described the FY26 performance as showing significant year-on-year growth across operations. These audited results provide the base for dividend consideration and capital allocation decisions. The board’s decision-making also reflected its stated focus on evaluating potential strategic avenues and corporate actions.

Standalone FY26 performance: faster top-line growth

On a standalone basis, revenue from operations for FY26 rose to ₹4,527.66 million from ₹3,514.11 million in FY25. Standalone net profit increased to ₹1,318.06 million from ₹1,024.20 million in the previous year. The company’s disclosure positioned the standalone numbers as another indicator of broad-based improvement in profitability. While the detailed segment commentary was not included in the provided information, the higher standalone revenue and profit underscore stronger core performance during the year. The standalone audited results were also covered by the statutory auditor’s report. Together, standalone and consolidated results form the basis for shareholder discussions at the AGM.

Q4 FY26 snapshot: revenue rise and profit jump noted

For Q4 FY26 (audited), consolidated revenue from operations was reported at ₹2,033.67 million, up from ₹1,671.79 million in Q4 FY25 (audited). The company also cited that Q4 FY26 net profit surged 69% year-on-year to ₹453 million. This quarter-level improvement was referenced alongside the full-year growth in revenue and profit. The Q4 print is important because it often shapes near-term market interpretation of operating trends. The company has not provided additional Q4 line-item detail in the text shared beyond the headline revenue comparison and the stated net profit jump. Investors typically use the audited Q4 and full-year figures as a reference point for understanding earnings quality and year-end adjustments.

Final dividend recommended, interim dividend deferred

The board recommended a final dividend of ₹1.35 per equity share for FY26, which remains subject to shareholder approval at the 37th AGM. At the same time, it decided to defer declaring an interim dividend. The company said the decision was taken to preserve capital flexibility while evaluating potential strategic avenues and corporate actions aimed at long-term shareholder value. The disclosure is notable because it signals a preference to keep cash available rather than committing to an additional interim payout at this stage. The company’s market data section also listed a dividend yield of 1.94% and confirmed the face value at ₹2.00 per share. Shareholders will vote on the proposed final dividend at the AGM.

ESOP allotment and change in paid-up share capital

Advanced Enzyme said the board approved the allotment of 49,350 equity shares of face value ₹2 each under the Advanced Enzyme Technologies Limited Employees Stock Options Scheme 2022. Following this allotment, the paid-up share capital increased from ₹223.8536 million (11,19,26,800 equity shares of ₹2 each) to ₹223.9523 million (11,19,76,150 equity shares of ₹2 each). The disclosure clarifies the precise before-and-after share count and capital amount resulting from ESOP exercises. Such allotments typically have a small dilution impact when compared with the overall equity base, but they are tracked closely by investors. The company communicated the resulting paid-up capital update as part of its exchange filing.

Audit outcome and governance notes

The statutory auditors, M S K A & Associates LLP, issued an unmodified audit opinion on both the standalone and consolidated financial results for FY26, according to the company’s disclosure. This indicates the auditors did not qualify their opinion on the FY26 audited numbers presented. The board also approved director reappointments and appointments, which are expected to be taken to shareholders at the AGM. These governance actions are routine parts of annual board and shareholder processes, particularly around the approval of audited results and dividends. Investors often track such agenda items for continuity in leadership and board oversight.

Analyst and investor conference call: schedule and contacts

Advanced Enzyme announced an earnings conference call for analysts and investors to discuss results for the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST. The company provided dial-in numbers: +91 86 3416 8438 / +91 86 4536 6489, and an international participant PIN: 4773312#. For investor relations, the company shared the contact details of Ronak Saraf (Investor Relations), email ir@advancedenzymes.com, and phone +91 86578 64146. It also stated that the conference call information has been uploaded on the company’s website.

Market check: stock move cited in the update

The material also referenced a stock move, stating that Advanced Enzyme Technologies Ltd. share price moved up 0.98% from its previous close of ₹266.40. The last traded price was stated as ₹269.00. While price moves can be influenced by broader market conditions, the cited change provides context for how the stock was trading around the time of the disclosure. Investors typically compare such moves against earnings outcomes, dividend decisions, and forward communication such as conference calls.

Summary table of disclosed figures

What investors will track next

The next key step is shareholder voting on the recommended final dividend at the 37th AGM, along with director reappointments and appointments. Separately, the May 12, 2026 conference call is expected to be the primary forum for management to address investor questions on FY26 and Q4 performance within the scope of disclosed results. The company has also stated that it deferred an interim dividend to preserve flexibility for potential strategic avenues and corporate actions, which will remain an area of attention for shareholders. Any further updates would typically come through exchange filings and subsequent board or AGM outcomes.